Core Insights - Glaukos reported $106.66 million in revenue for Q1 2025, a 24.6% year-over-year increase, with an EPS of -$0.22 compared to -$0.70 a year ago, exceeding the Zacks Consensus Estimate of $102.72 million by 3.84% [1] - The company achieved an EPS surprise of 33.33%, with the consensus EPS estimate being -$0.33 [1] Revenue Breakdown - U.S. revenues reached $75.07 million, surpassing the average estimate of $71.54 million, reflecting a 30.1% year-over-year increase [4] - International revenues totaled $31.59 million, slightly above the average estimate of $31.35 million, marking a 13.1% year-over-year increase [4] - Corneal Health revenues in the international market were $2.59 million, below the average estimate of $2.78 million, showing a decline of 4.1% year-over-year [4] - U.S. Corneal Health revenues were $15.94 million, exceeding the average estimate of $15.50 million, with a 1.5% year-over-year increase [4] - International Glaucoma revenues amounted to $29.01 million, surpassing the average estimate of $28.57 million, reflecting a 14.9% year-over-year increase [4] - U.S. Glaucoma revenues reached $59.13 million, exceeding the average estimate of $56.03 million, with a significant 40.8% year-over-year increase [4] - Total Corneal Health revenues were $18.53 million, slightly above the average estimate of $18.28 million, representing a 0.7% year-over-year increase [4] - Total Glaucoma revenues were $88.14 million, exceeding the average estimate of $84.60 million, reflecting a 31.1% year-over-year increase [4] Stock Performance - Glaukos shares have returned -5.8% over the past month, compared to the Zacks S&P 500 composite's -0.7% change, with a current Zacks Rank of 3 (Hold) indicating potential performance in line with the broader market [3]

Financial Performance - For the quarter ended March 2025, Sprouts Farmers (SFM) reported revenue of $2.24 billion, an increase of 18.7% year-over-year [1] - EPS for the quarter was $1.81, up from $1.12 in the same quarter last year [1] - The reported revenue exceeded the Zacks Consensus Estimate of $2.2 billion, resulting in a surprise of +1.88% [1] - The company delivered an EPS surprise of +17.53%, with the consensus EPS estimate being $1.54 [1] Key Metrics - Comparable store sales growth was 11.7%, surpassing the average estimate of 10.7% based on four analysts [4] - The number of stores at the end of the period was 443, slightly below the four-analyst average estimate of 444 [4] - Three new stores were opened, compared to an average estimate of four by three analysts [4] - The number of stores at the beginning of the period was 440, matching the two-analyst average estimate [4] Stock Performance - Shares of Sprouts Farmers have returned +11% over the past month, while the Zacks S&P 500 composite experienced a -0.2% change [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential outperformance against the broader market in the near term [3]

Core Insights - Ionis Pharmaceuticals reported revenue of $132 million for the quarter ended March 2025, reflecting a year-over-year increase of 10.9% and surpassing the Zacks Consensus Estimate of $120.16 million by 9.86% [1] - The company's EPS was -$0.75, an improvement from -$0.98 in the same quarter last year, with an EPS surprise of 32.43% against a consensus estimate of -$1.11 [1] Revenue Breakdown - Commercial revenue from SPINRAZA royalties was $48 million, exceeding the average estimate of $43.02 million by nine analysts, marking a 26.3% increase year over year [4] - Total commercial revenue reached $76 million, surpassing the average estimate of $66.61 million based on eight analysts, representing a 28.8% year-over-year change [4] - Total research and development revenue was $56 million, compared to the average estimate of $50.44 million [4] - WAINUA royalties generated $9 million, slightly below the average estimate of $9.89 million [4] - Other commercial revenue from TEGSEDI and WAYLIVRA was $6 million, falling short of the average estimate of $6.93 million, indicating a 33.3% decline year over year [4] - Collaborative agreement revenue within research and development was $46 million, exceeding the average estimate of $37.10 million, but reflecting a 6.1% decrease year over year [4] Stock Performance - Ionis Pharmaceuticals' shares have returned +9.4% over the past month, contrasting with a -0.2% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

For the quarter ended March 2025, Woodward (WWD) reported revenue of $883.63 million, up 5.8% over the same period last year. EPS came in at $1.69, compared to $1.62 in the year-ago quarter.The reported revenue represents a surprise of +6.43% over the Zacks Consensus Estimate of $830.26 million. With the consensus EPS estimate being $1.44, the EPS surprise was +17.36%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their ...

Core Insights - NXP Semiconductors reported a revenue of $2.84 billion for Q1 2025, reflecting a year-over-year decline of 9.3% and an EPS of $2.64, down from $3.24 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $2.83 billion by 0.30%, while the EPS surpassed the consensus estimate of $2.59 by 1.93% [1] Revenue Breakdown - Automotive revenue was $1.67 billion, slightly below the average estimate of $1.69 billion, marking a year-over-year decline of 7.2% [4] - Communications Infrastructure & Other revenue reached $315 million, exceeding the average estimate of $302.16 million, but showing a significant year-over-year decline of 21.1% [4] - Industrial & IoT revenue was $508 million, slightly below the average estimate of $512.51 million, with a year-over-year decline of 11.5% [4] - Mobile revenue was $338 million, surpassing the average estimate of $325.45 million, but still reflecting a year-over-year decline of 3.2% [4] Stock Performance - NXP shares have returned +1.9% over the past month, contrasting with a -4.3% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]

Alexandria Real Estate Equities (ARE) reported $758.2 million in revenue for the quarter ended March 2025, representing a year-over-year decline of 1.4%. EPS of $2.30 for the same period compares to $0.97 a year ago. View all Key Company Metrics for Alexandria Real Estate Equities here>>> The reported revenue compares to the Zacks Consensus Estimate of $749.53 million, representing a surprise of +1.16%. The company delivered an EPS surprise of +0.88%, with the consensus EPS estimate being $2.28. Shares of A ...

Welltower (WELL) reported $2.42 billion in revenue for the quarter ended March 2025, representing a year- over-year increase of 30.3%. EPS of $1.20 for the same period compares to $0.22 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $2.37 billion, representing a surprise of +2.12%. The company delivered an EPS surprise of +4.35%, with the consensus EPS estimate being $1.15. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Str ...

View all Key Company Metrics for Domino's Pizza here>>> While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps inve ...

Core Insights - Colgate-Palmolive reported revenue of $4.91 billion for Q1 2025, a year-over-year decline of 3%, but exceeded Zacks Consensus Estimate by 1.15% [1] - The company's EPS for the quarter was $0.91, up from $0.86 a year ago, representing a surprise of 5.81% over the consensus estimate [1] Revenue Performance by Region - North America: Net sales of $998 million, slightly below the estimated $1 billion, with a year-over-year change of +0.1% [4] - Latin America: Net sales of $1.14 billion, exceeding the $1.09 billion estimate, but down 8.8% year-over-year [4] - Africa/Eurasia: Net sales of $271 million, slightly below the $273.66 million estimate, with a year-over-year decline of 1.8% [4] - Europe: Net sales of $690 million, above the $674.15 million estimate, reflecting a year-over-year decline of 3% [4] - Asia Pacific: Net sales of $690 million, below the $727.36 million estimate, with a year-over-year decline of 5.1% [4] - Pet Nutrition: Net sales of $1.12 billion, exceeding the $1.09 billion estimate, with a year-over-year increase of 1.5% [4] - Total Oral, Personal and Home Care: Net sales of $3.79 billion, slightly above the $3.77 billion estimate, with a year-over-year decline of 4.3% [4] Operating Profit Analysis - Total Oral, Personal and Home Care: Operating profit of $971 million, below the estimated $1.01 billion [4] - Corporate: Operating profit of -$153 million, better than the estimated -$182.49 million [4] - Pet Nutrition: Operating profit of $258 million, exceeding the $239.30 million estimate [4] Stock Performance - Colgate-Palmolive shares returned -0.5% over the past month, compared to the Zacks S&P 500 composite's -4.8% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market [3]

Core Insights - Intel's recent earnings report and management comments indicate a focus on future growth and strategic direction [1] Financial Performance - The earnings report highlights Intel's financial results for the recent quarter, showcasing key metrics that reflect the company's performance [1] Management Outlook - Management provided insights into the company's future plans, emphasizing areas of investment and growth potential [1]